Civic Data
FDA RecallsUSDA RecallsAbout

FDA Recalls

  • Food recalls
  • Drug recalls
  • Device recalls

USDA Recalls

  • All USDA recalls
  • Poultry recalls
  • Meat recalls
  • Egg recalls

About

  • About us
  • FDA guides
  • USDA guides
  • Data sources
  • Privacy policy

Data

  • OpenFDA API
  • USDA FSIS

© 2026Civic Data · Data sourced from OpenFDA and USDA FSIS · Not affiliated with the U.S. Food and Drug Administration or the U.S. Department of Agriculture · Always verify against official sources before acting

  1. FDA Recalls
  2. ›Drug Recalls

FDA Drug Recalls

Recalls of prescription drugs, over-the-counter medications, and compounded pharmaceuticals.

Classification
AllClass IClass IIClass III
Status
AllOngoingCompletedTerminated
Date
All timePast 30 daysPast 12 months

Showing 141–160 of 1,000 recalls

Class IIICompleted

Valacyclovir Tablets USP, 500 mg, 90 count bottles, Rx Only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 USA, NDC 0378-4275-77

Viatris Inc

Failed Tablet/Capsule Specifications: There is a potential for the imprint, M 122, to be missing on some tablets.

April 25, 2024 · DrugView details →
Class IIITerminated

Sodium Sulfacetamide 10% - Sulfur 5% Cleanser, Rx Only, 6 oz (170.3 g) Bottle, Manufactured for Acela Pharmaceuticals, LLC Alphareta, GA 30005, NDC 42192-136-06

Acella Pharmaceuticals, LLC

Subpotent drug

April 24, 2024 · DrugView details →
Class IIIOngoing

Xelpros (latanoprost ophthalmic emulsion) 0.005%, 125mcg/2.5mL, 2.5 mL bottle, Rx only, Manufactured by: Sun Pharmaceutical Ind. Ltd., India., NDC 47335-317-90

SUN PHARMACEUTICAL INDUSTRIES INC

Failed Release Testing: Out of specification for particulate matter test.

April 22, 2024 · DrugView details →
Class IIIOngoing

Epinephrine-Lidocaine HCl 0.25 mg/mL and 7.5 mg/mL Preservative-Free, 1 mL Single-Use vials, Rx only, Imprimis NJOF, LLC 1705 Route 46 West, Unit 6B, Ledgewood, NJ, 07852, NDC 71384-640-01

Imprimis NJOF, LLC

Out of specification for assay

April 10, 2024 · DrugView details →
Class IIIOngoing

Abilify (aripiprazole), 15 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-009-13

Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.

Cross Contamination with Other Products

April 9, 2024 · DrugView details →
Class IIIOngoing

Abilify (aripiprazole), 5 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-007-13

Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.

Cross Contamination with Other Products

April 9, 2024 · DrugView details →
Class IIIOngoing

Abilify (aripiprazole), 10 mg tablets, packaged in a) 30 count bottles (NDC 59148-008-13) and b) 7 count blister packs (NDC 59148-008-95), RX only, Otsuka America Pharmaceutical, Inc.

Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.

Cross Contamination with Other Products

April 9, 2024 · DrugView details →
Class IIIOngoing

Abilify (aripiprazole), 30 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-011-13

Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.

Cross Contamination with Other Products

April 9, 2024 · DrugView details →
Class IIITerminated

Cyclophosphamide for Injection, USP, 1g/vial, Lyophilized, Single Dose Vial, Discard unused solution, Cytotoxic Agent, After Reconstitution: For direct intravenous injection or must be further diluted before intravenous infusion, Rx Only, Manufactured for: XGen Pharmaceuticals DJB, Inc., Big Flats, NY 14814, NDC # 39822-0255-01.

X-Gen Pharmaceuticals Inc.

Labeling: Incorrect or missing Package Insert: There is an error on the Package Insert (PI), section 2.3, Preparation, Handling, and Administration. The concentration of the reconstituted product is listed as '20 mg per vial.' This information should read: '20 mg per mL'.

April 2, 2024 · DrugView details →
Class IIITerminated

Cyclophosphamide for Injection, USP, 500mg/vial, Lyophilized, Cytotoxic Agent, Single Dose Vial for Intravenous Use, Rx Only, Manufactured for: XGen Pharmaceuticals DJB, Inc. Big Flats, NY 14814, NDC # 39822-0250-01.

X-Gen Pharmaceuticals Inc.

Labeling: Incorrect or missing Package Insert: There is an error on the Package Insert (PI), section 2.3, Preparation, Handling, and Administration. The concentration of the reconstituted product is listed as '20 mg per vial.' This information should read: '20 mg per mL'.

April 2, 2024 · DrugView details →
Class IIICompleted

NEXLIZET (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg, 30-count bottle, Rx only, Manufactured for: Esperion Therapeutics, Ann Arbor, MI 48108, NDC 72426-818-03

Esperion

Failed dissolution specifications: out-of-specification bempedoic acid dissolution at the 0-month timepoint.

March 27, 2024 · DrugView details →
Class IIITerminated

Digoxin Tablets, USP 62.5 mcg (0.0625 mg), 100-count bottles, Rx Only, Manufactured by: Novitium Pharma LLC, 70 Lake Drive, East Windsor, New Jersey 08520, NDC 70954-200-10

Novitium Pharma LLC

Failed Impurities/Degradation Specifications

March 25, 2024 · DrugView details →
Class IIITerminated

Digoxin Tablets, USP 125mcg, (0.125 mg), 1000-count bottle, Rx Only, Manufactured by: Novitium Pharma LLC., 70 Lake Drive, East Windsor, New Jersey 08520, NDC 70954-201-20

Novitium Pharma LLC

Cross Contamination with Other Products:(mycophenolate mofetil).

March 4, 2024 · DrugView details →
Class IIIOngoing

Clindamycin Phosphate, Topical Solution USP, 1%, 60 mL, Rx Only, Manufactured for and Distributed by: Marlex Pharmaceuticals, Inc., New Castle, DE 19720, NDC 10135-0691-61

Contract Pharmaceuticals Limited Canada

Defective Container: Out of specification for weight due to a slow leakage at the 12-month stability timepoint.

February 20, 2024 · DrugView details →
Class IIIOngoing

Clindamycin Phosphate Topical Solution USP, 1%, 60 mL bottle, Manufactured for: Glasshouse Pharmaceuticals Limited Canada, Mississauga, Ontario, Canada, L5N 6R8, NDC 71428-0003-60

Contract Pharmaceuticals Limited Canada

Defective Container: Out of specification for weight due to a slow leakage at the 12-month stability timepoint.

February 20, 2024 · DrugView details →
Class IIITerminated

Mercaptopurine Tablets, USP 50 mg, packaged in: a) 25-count bottle (NDC 69076-913-02), b) 250-count bottle (NDC 69076-913-25), Rx only, Manufactured for: Quinn Pharmaceuticals, Boca Raton, FL, www.quinnrx.com

Stason Pharmaceuticals, Inc.

Failed Dissolution Specifications: results slightly under spec at at 9-months.

February 9, 2024 · DrugView details →
Class IIIOngoing

HydrALAZINE Hydrochloride Tablets, USP, 10 mg, 100-count (10 x 10) per unit dose carton, Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217. NDC Carton: 68084-447-01; NDC Unit Dose: 68084-447-11

Amerisource Health Services LLC

Failed Impurities/Degradation Specifications: Out of Specification (OOS) result in the repackaged product for Related Compounds (Impurities) at the 6-month time point.

February 1, 2024 · DrugView details →
Class IIIOngoing

Nortrel (norethindrone and ethinyl estradiol tablets USP) 0.5/35, packaged in cartons, each carton contains 3 blister cards, each card contains 28 tablets, Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0555-9008-67

Teva Pharmaceuticals USA, Inc

Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.

January 25, 2024 · DrugView details →
Class IIIOngoing

Nortrel 7/7/7 (norethindrone and ethinyl estradiol tablets USP- triphasic regimen), packaged in cartons, each carton contains 6 blister cards, each card contains 28 tablets, Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0555-9012-58

Teva Pharmaceuticals USA, Inc

Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.

January 25, 2024 · DrugView details →
Class IIIOngoing

Glimepiride Tablets, USP 1mg, 500-count bottles, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Srikakulam-532 409 INDIA, NDC: 55111-320-05

Dr. Reddy's Laboratories, Inc.

Misprint on tablet

January 18, 2024 · DrugView details →
← PreviousPage 8 of 50Next →